Cancer epigenetics drug discovery and development: the challenge of hitting the mark - Wikidata - wikimedia - TriplyDB

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

http://www.wikidata.org/entity/Q27002333

about

The retinal determination gene network: from developmental regulator to cancer therapeutic target Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigations Potential of epigenetic therapies in the management of solid tumors Environmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer Prevention Back to the future: transgenerational transmission of xenobiotic-induced epigenetic remodeling Predictive value of epigenetic alterations in head and neck squamous cell carcinoma HEDD: the human epigenetic drug database Chemical Proteomic Profiling of Human Methyltransferases Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma.Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output.The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies Remaining challenges in childhood cancer and newer targeted therapeutics.Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.Targeting epigenetic regulations in cancer Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.DNA Methylation Indicates Susceptibility to Isoproterenol-Induced Cardiac Pathology and Is Associated With Chromatin States.Squamous Cell Cancers: A Unified Perspective on Biology and Genetics Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis.Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer.Epigenetic targets for novel therapies of lung diseases.Effects of deranged metabolism on epigenetic changes in cancer.Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives.Prospects for the development of epigenetic drugs for CNS conditions.Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.Histone Modifications and Asthma. The Interface of the Epigenetic and Genetic Landscapes.SAM/SAH Analogs as Versatile Tools for SAM-Dependent Methyltransferases.Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis.Histone Modifications and Cancer.Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression.Environmental influences in the etiology of colorectal cancer: the premise of metabolomics.Large-Scale Overproduction and Purification of Recombinant Histone Deacetylase 8 (HDAC8) from the Human-Pathogenic Flatworm Schistosoma mansoni.Functional AdoMet Isosteres Resistant to Classical AdoMet Degradation Pathways.The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer.HDAC8 and STAT3 repress BMF gene activity in colon cancer cells.

P2860

Q26747218-42FF98A2-7836-45AC-BF6B-BDE418041C95 Q26778780-5330AE58-403C-437B-831A-007FE592E963 Q26781745-4A1E1512-2A91-4E14-AA89-E92A8FF9AF2A Q26783134-AAE70D54-4DCD-409D-AEA5-6233D49C17FE Q26784500-503F0015-7E3C-4B3A-AD37-EEE40653FB2E Q26852391-7A92884A-0C5C-475E-BFDE-4DB876E76D06 Q27690755-B100F6C4-BAAE-4AAA-B972-3277584D6440 Q28818364-37FF569E-A6FE-4C53-803F-A172A957BDAB Q28821490-10C821A3-E291-4EDE-95AD-AEB1DCABB435 Q33292152-641E6F93-B315-429F-9C64-CCFD1A082376 Q33970149-FEC43F6A-664C-4961-A267-EBC1A615A3E3 Q34281240-D5F306A8-7205-4842-B90F-B8D1B228AB63 Q34619156-D63BD0BC-77E9-46F6-A28F-9CC22E99B22C Q35106844-E894DEEA-B5A9-4F32-B144-732E89EB123E Q35133549-65BFD845-42BA-4B82-A1C1-3066B9AD0715 Q35662225-14A4AD9B-0FBB-4886-BE3F-4E207D06B8F3 Q36398751-0F9C5449-5226-412F-8F7B-96D37936A7B8 Q36627526-EAE97FCF-3694-4E10-8C37-03A82F2A0686 Q36654978-E9605633-9D18-4EE0-B4CF-7D779F3D6B25 Q36909843-2B16F01A-CF62-4706-9E47-FCF311FDF650 Q37149776-58D2F890-F34E-4BC6-AB1E-165EF12456C7 Q37265792-E6003AB8-2FEA-4042-BFEC-92E5707484CC Q37628942-09E54196-E051-4112-BE87-59468582075C Q38275276-701A7969-DB09-4028-B26E-E199A29F93B3 Q38335029-68C92DAE-3EFB-4D38-851C-98290BD98F37 Q38495057-6027FE47-3BB3-4D05-BE31-B7D69F7B981A Q38497844-B4775302-CB66-4A99-B671-363EB277B7EA Q38542092-E2EC9372-00EA-48EE-B251-4674FA4A1DC3 Q38591399-995F263D-C027-4316-A500-D5123D008CF8 Q38625953-514CEC7F-2D2A-4EC0-A400-08C750DE2C94 Q38637046-25E61F44-8E29-49B4-99FF-DEB274158DB0 Q38694375-4B027C99-8ABC-4E9E-ABE1-0F26353B6984 Q38796064-64145EEF-C17A-48BF-A89E-F6893A28D28E Q38909048-53CE9170-C48D-4795-AFED-BC0BD32466DE Q39392886-7229BF13-E24D-45D7-8B3F-2EFB8B98F697 Q40651231-1513C866-F869-4585-93C9-5A897DED951E Q41112322-3E10B8AA-322F-4878-B9D5-7CB747ED7456 Q41841298-FC40EC68-DE2E-469A-B1E8-E05EB7F692CD Q42049687-081C6FA4-FDD1-4327-B47A-4154385BE4DA Q42703854-FB114D40-918C-49ED-8F35-EB9A37B0B4DA

P2860

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

http://www.wikidata.org/entity/Q27002333

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@ast

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@en

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@nl

type

label

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@ast

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@en

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@nl

prefLabel

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@ast

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@en

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@nl

P1433

Q27002333-288A98E0-676C-4038-8FD0-2C4651269E94

P1476

Q27002333-7396C824-BF6A-4BC4-AF34-F20145586129

P2093

Q27002333-61ED1878-1BC9-488E-9FFB-DC3A043BD4AD

Q27002333-DD16CB30-B5E1-41E6-A56C-800AA918570A

P2860

Q27002333-043E6432-EBE9-48EA-B9B7-26E2766EBDB0

Q27002333-05FD7D32-BC53-4130-86C6-666C0E7348F2

Q27002333-07C9D3E5-0DAB-4C7D-B256-10E2F4EB9D36

Q27002333-11723363-A95F-42FE-83AC-64D2A318DBDD

Q27002333-1222C25E-E82D-4C42-8C4C-8DE1678D18B3

Q27002333-1D12D78A-5163-4CCB-A9A5-DE30585D1474

Q27002333-225C3EC2-0099-4F6A-B312-1BCF8106F42E

Q27002333-26C722E3-EC09-439B-8424-5DBC433F4CED

Q27002333-27520262-1F67-4E18-B99A-B421F97E8B85

Q27002333-28B930C3-235A-470E-A259-8A27763D439B

P304

Q27002333-EE42996F-DF4D-4E51-A9A9-DB5F92E94C25

P31

Q27002333-9BC80B82-687F-4C38-B69B-87D3D11000B5

P3181

Q27002333-857F78F3-C9F1-4285-9992-1A62F34DC967

P356

Q27002333-9F3E3A71-0B80-4FA5-8839-600E807421B8

P407

Q27002333-4B74FC7F-8933-4A75-A018-090B2A3D12D0

P433

Q27002333-3A82DC35-0675-4455-947F-CABCFE648089

P478

Q27002333-BC2882B7-8FFB-4BDC-B932-D939CEF67E82

P577

Q27002333-A0A1521E-2441-4FDF-B98D-B9CCA0D54B84

P698

Q27002333-11FA28C7-3F7B-4511-A9C5-15E99D3F9FEB

P921

Q27002333-D0AC02CE-EB44-49FA-BCAB-45A78766C046

P932

Q27002333-E94FBD19-0F7F-47FD-AEA5-49DAD25416D7

P3181

P356

P1433

Journal of Clinical Investigation

P1476

Cancer epigenetics drug discovery and development: the challenge of hitting the mark

@en

P2093

Peter J. Tummino

http://www.w3.org/2001/XMLSchema#string

Robert M. Campbell

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

A decade of exploring the cancer epigenome - biological and translational implications

A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells

Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors

CpG island methylator phenotype in colorectal cancer

Role of the polycomb protein EED in the propagation of repressive histone marks

Suppression of inflammation by a synthetic histone mimic

Discovery and characterization of small molecule inhibitors of the BET family bromodomains

Selective Inhibitors of Histone Methyltransferase DOT1L: Design, Synthesis, and Crystallographic Studies

P304

64-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4833671

http://www.w3.org/2001/XMLSchema#string

P356

10.1172/JCI71605

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24382391

http://www.w3.org/2001/XMLSchema#string

P921

P932

3871251

http://www.w3.org/2001/XMLSchema#string